Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Three factors to unlock the value of AI for life sciences

Posted on May 1st, 2019 by in Pharma R&D

Artificial Intelligence (AI) has been at the top of many boardroom agendas for the last several years, as execs try to integrate the technology. Recent RELX research found that, across all industries, 88 percent of senior executives believe AI will help their businesses be more competitive. In the life sciences, AI has the potential to scale the benefits of precision medicine or automated disease prediction to more patients across the world, and could generate more than $150 billion in savings for the healthcare industry by 2025. 

3d rendering robot hand working with security laptop
(more…)

Working together to get the best out of AI for all

Posted on April 16th, 2019 by in Pharma R&D

Go to any conference these days and the number one buzzword is AI. However, despite all the excitement, AI is still talked about in fairly vague terms – with few people able to pin down exactly what they mean by AI. New research from some of my Elsevier colleagues examined this phenomenon.

(more…)

Data-Driven Technologies are Shaking Up the Drug Development Process

Posted on March 15th, 2019 by in Pharma R&D

For many, many years, the findings of scientific research were published in an always-growing collection of scientific journals that spun off into more and more specialized disciplines. Today’s scientists have to think far beyond scholarly journals subscriptions and wrestle instead with search strategies and informatics.

(more…)

Pharma Industry Players Work Together to Raise Awareness and Find Cures for Rare Diseases

Posted on February 28th, 2019 by in Pharma R&D

On February 28, events around the world are held in honor of Rare Disease Day, an annual occasion designed to raise awareness among the general public as well as among policy makers, government bodies, healthcare professionals and researchers. Rare diseases have become a major focus for cross-industry collaborations in recent years, and for good reason: (more…)

  1. 1
  2. 2
  3. 3